Kiniksa, Kite in Mavrilimumab Collaboration
December 11 2019 - 9:38AM
Dow Jones News
By Chris Wack
Kite, a Gilead Sciences Inc. (GILD) company, and Kiniksa
Pharmaceuticals Ltd. (KNSA) said Wednesday that they will be
collaborating in a Phase 2, multicenter study of mavrilimumab, a
investigational fully human monoclonal antibody, in combination
with Yescarta axicabtagene ciloleucel in patients with relapsed or
refractory large B-cell lymphoma.
The companies said the study aims to determine the effect of
mavrilimumab on the safety of Yescarta. Kite will conduct the
study.
Mavrilimumab hasn't been approved by the U.S. Food and Drug
Administration or any regulatory authority for any uses. Efficacy
and safety of the antibody haven't been established.
Kiniksa shares were up 7% to $13.84 premarket, while Gilead
shares were up 1%.
Write to Chris Wack at chris.wack@wsj.com
(END) Dow Jones Newswires
December 11, 2019 09:23 ET (14:23 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
Kiniksa Pharmaceuticals (NASDAQ:KNSA)
Historical Stock Chart
From Aug 2024 to Sep 2024
Kiniksa Pharmaceuticals (NASDAQ:KNSA)
Historical Stock Chart
From Sep 2023 to Sep 2024